Latest Healthcare Research Reports

Tag: pain management

  • Facet-Joint Injection Market Forecast Showing Industry Progress And Growth Trends

    Facet-Joint Injection Market Forecast Showing Industry Progress And Growth Trends

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Will The Market Value Of The Facet-Joint Injection Market Progress Between 2026 And 2030?

    The market for facet-joint injections has experienced significant expansion recently. This market is projected to expand from $2.97 billion in 2025 to reach $3.18 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.9%. Historically, this growth can be attributed to factors such as the prevalence of spinal degeneration, the incidence of arthritis, increased awareness of pain management techniques, the utilization of corticosteroids, and the rise in outpatient procedures.

    The facet-joint injection market size is anticipated to experience robust expansion over the coming years. It is projected to reach $4.1 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is driven by factors such as an aging population, a preference for minimally invasive treatments, the widespread occurrence of chronic pain, the growth of ambulatory care, and the use of imaging-guided procedures. Key developments expected in this period include an increasing need for minimally invasive pain interventions, greater application in managing chronic back pain, the proliferation of outpatient pain clinics, the adoption of image-guided injection methods, and the broadening of ambulatory surgical centers.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

    What Primary Drivers Are Shaping The Facet-Joint Injection Market?

    The increasing occurrence of spinal diseases and persistent back pain is anticipated to fuel the expansion of the facet-joint injection market in the coming years. These conditions encompass long-standing ailments impacting the spine, such as disc degeneration, arthritis, or nerve compression, which result in continuous discomfort, restricted movement, and a diminished quality of life. The surge in spinal diseases and chronic back pain can be attributed to inactive lifestyles and improper posture, prompting individuals to seek efficacious, minimally disruptive treatments to alleviate ongoing discomfort and restore functional movement. Facet-joint injection offers relief for spinal diseases and chronic back pain by diminishing spinal pain and inflammation. For instance, in May 2023, Spinal Cord Inc., a US-based non-profit resource center, reported approximately 18,000 new spinal cord injury (SCI) cases annually in the United States in 2023, with an estimated 302,000 individuals presently living with spinal cord injuries nationwide. Consequently, the growing prevalence of spinal diseases and chronic back pain is a significant factor propelling the facet-joint injection market’s growth.

    What Are The Main Segments Within The Facet-Joint Injection Market Segment Structure?

    The facet-joint injection market covered in this report is segmented –

    1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

    2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

    3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

    2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

    3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

    4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

    What Trends Are Affecting The Growth Of The Facet-Joint Injection Market?

    Major companies operating in the facet-joint injection market are concentrating their efforts on developing innovative offerings, such as facet fusion systems, to provide more enduring relief and enhance therapeutic results. Facet fusion systems are defined as medical devices engineered to stabilize and join the spine’s facet joints by encouraging bone development between adjacent vertebrae. As an illustration, in March 2025, Aurora Spine Corporation, a US-based medical device company, announced that the AEROTM Facet Fusion System, its newest product, had secured 510(k) clearance from the U.S. Food and Drug Administration (FDA). This system incorporates a titanium plasma spray coating to boost osseointegration and its capacity for fusion. Furthermore, it supports various implant sizes to suit diverse patient anatomies and includes radiolucent instrumentation to improve visibility during operations. These combined attributes are intended to enhance the effectiveness of procedures and the long-term prognosis for individuals suffering from chronic back pain originating from facet joint disorders.

    Who Are The Companies Participating In The Facet-Joint Injection Market?

    Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

    Get The Full Facet-Joint Injection Market Report:

    https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

    Which Region Is The Leading Market For The Facet-Joint Injection Market?

    North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Facet-Joint Injection Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

    Browse Through More Reports Similar to the Global Facet-Joint Injection Market 2026, By The Business Research Company

    Self Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/self-injections-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Facial Injectable Market Report 2026

    https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Facet-Joint Injection Market Forecast Showing Industry Progress And Growth Trends

    Facet-Joint Injection Market Forecast Showing Industry Progress And Growth Trends

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    How Will The Market Value Of The Facet-Joint Injection Market Progress Between 2026 And 2030?

    The market for facet-joint injections has experienced significant expansion recently. This market is projected to expand from $2.97 billion in 2025 to reach $3.18 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.9%. Historically, this growth can be attributed to factors such as the prevalence of spinal degeneration, the incidence of arthritis, increased awareness of pain management techniques, the utilization of corticosteroids, and the rise in outpatient procedures.

    The facet-joint injection market size is anticipated to experience robust expansion over the coming years. It is projected to reach $4.1 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is driven by factors such as an aging population, a preference for minimally invasive treatments, the widespread occurrence of chronic pain, the growth of ambulatory care, and the use of imaging-guided procedures. Key developments expected in this period include an increasing need for minimally invasive pain interventions, greater application in managing chronic back pain, the proliferation of outpatient pain clinics, the adoption of image-guided injection methods, and the broadening of ambulatory surgical centers.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

    What Primary Drivers Are Shaping The Facet-Joint Injection Market?

    The increasing occurrence of spinal diseases and persistent back pain is anticipated to fuel the expansion of the facet-joint injection market in the coming years. These conditions encompass long-standing ailments impacting the spine, such as disc degeneration, arthritis, or nerve compression, which result in continuous discomfort, restricted movement, and a diminished quality of life. The surge in spinal diseases and chronic back pain can be attributed to inactive lifestyles and improper posture, prompting individuals to seek efficacious, minimally disruptive treatments to alleviate ongoing discomfort and restore functional movement. Facet-joint injection offers relief for spinal diseases and chronic back pain by diminishing spinal pain and inflammation. For instance, in May 2023, Spinal Cord Inc., a US-based non-profit resource center, reported approximately 18,000 new spinal cord injury (SCI) cases annually in the United States in 2023, with an estimated 302,000 individuals presently living with spinal cord injuries nationwide. Consequently, the growing prevalence of spinal diseases and chronic back pain is a significant factor propelling the facet-joint injection market’s growth.

    What Are The Main Segments Within The Facet-Joint Injection Market Segment Structure?

    The facet-joint injection market covered in this report is segmented –

    1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

    2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

    3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

    2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

    3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

    4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

    What Trends Are Affecting The Growth Of The Facet-Joint Injection Market?

    Major companies operating in the facet-joint injection market are concentrating their efforts on developing innovative offerings, such as facet fusion systems, to provide more enduring relief and enhance therapeutic results. Facet fusion systems are defined as medical devices engineered to stabilize and join the spine’s facet joints by encouraging bone development between adjacent vertebrae. As an illustration, in March 2025, Aurora Spine Corporation, a US-based medical device company, announced that the AEROTM Facet Fusion System, its newest product, had secured 510(k) clearance from the U.S. Food and Drug Administration (FDA). This system incorporates a titanium plasma spray coating to boost osseointegration and its capacity for fusion. Furthermore, it supports various implant sizes to suit diverse patient anatomies and includes radiolucent instrumentation to improve visibility during operations. These combined attributes are intended to enhance the effectiveness of procedures and the long-term prognosis for individuals suffering from chronic back pain originating from facet joint disorders.

    Who Are The Companies Participating In The Facet-Joint Injection Market?

    Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

    Get The Full Facet-Joint Injection Market Report:

    https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

    Which Region Is The Leading Market For The Facet-Joint Injection Market?

    North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Facet-Joint Injection Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

    Browse Through More Reports Similar to the Global Facet-Joint Injection Market 2026, By The Business Research Company

    Self Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/self-injections-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Facial Injectable Market Report 2026

    https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • A Notable Trend in the Lumbosacral Radicular Pain Management Market Is the Development of Non-Opioid Therapies Targeting Nav1.8

    A Notable Trend in the Lumbosacral Radicular Pain Management Market Is the Development of Non-Opioid Therapies Targeting Nav1.8

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Forecasted Market Value Of The Lumbosacral Radicular Pain Management Market Across 2026–2030?

    The lumbosacral radicular pain management market size has seen robust growth in recent years. It is projected to expand from $0.9 billion in 2025 to $0.95 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. This growth witnessed in the past can be attributed to an increase in cases of spinal disc disorders, a reliance on pharmacological pain relief, the provision of hospital-based pain treatment, a rise in orthopedic consultations, and the development of physical therapy services.

    The lumbosacral radicular pain management market is projected to experience robust expansion over the coming years. This market is anticipated to reach $1.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. Key drivers for this growth during the projected period include the increasing aging population, a rising need for long-term pain management solutions, the uptake of non-invasive treatments, the expansion of home-based rehabilitation services, and innovations in pain diagnostics. Significant trends expected during this forecast span encompass a surging preference for multimodal pain management approaches, the greater embrace of non-opioid therapies, an increase in physical therapy-based interventions, the growing call for minimally invasive pain procedures, and the incorporation of personalized pain management strategies.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24592&type=smp

    What Major Growth Drivers Are Shaping The Outlook Of The Lumbosacral Radicular Pain Management Market?

    The increasing occurrence of back ailments is anticipated to fuel the expansion of the lumbosacral radicular pain management market moving ahead. These disorders encompass various conditions impacting the spine, its muscles, or nerves within the back, leading to unease or discomfort. The growing frequency of back pain issues stems from inactive lifestyles, which contribute to weakened back muscles, resulting in poor posture and ongoing pain. The goal of lumbosacral radicular pain management is to alleviate irritation of nerve roots in the lower back, thereby decreasing pain and inflammation. This management approach helps restore mobility and enhances the overall quality of life. As an illustration, in June 2024, data from the Australian Institute of Health and Welfare, a government agency located in Australia, indicated that in 2023, back issues constituted the third principal factor contributing to the disease burden in Australia, accounting for 4.3% of the country’s total disease burden. Consequently, the increasing incidence of back pain disorders is a key driver for the expansion of the lumbosacral radicular pain management market.

    What Segmentation Levels Are Considered In The Lumbosacral Radicular Pain Management Market?

    The lumbosacral radicular pain management market covered in this report is segmented –

    1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

    2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

    3) By Route Of Administration: Oral, Topical

    4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

    Subsegments:

    1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

    2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

    3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

    4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

    5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

    What Trends Are Projected To Affect The Lumbosacral Radicular Pain Management Market?

    Key companies operating in the lumbosacral radicular pain management market are prioritizing the development of advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to deliver a non-opioid alternative for enduring pain relief. An investigational oral NaV1.8 pain signal inhibitor is a medication in its trial stage that specifically targets the NaV1.8 sodium channel, recognized as a primary pathway for pain transmission through sensory nerves. For instance, in December 2024, Vertex Pharmaceuticals, a US-based biotech firm, released the outcomes from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study successfully achieved its primary endpoint, revealing a statistically significant and clinically meaningful reduction in pain from baseline in the suzetrigine group. Suzetrigine was generally well-tolerated, with no serious adverse events reported. Vertex intends to address the notable placebo response in subsequent Phase 3 trials to more accurately assess the drug’s efficacy.

    Which Leading Firms Are Contributing To The Growth Of The Lumbosacral Radicular Pain Management Market?

    Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

    Read the full lumbosacral radicular pain management market report here:

    https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report

    Which Regions Are Projected To Dominate The Lumbosacral Radicular Pain Management Market In The Coming Years?

    North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Lumbosacral Radicular Pain Management Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24592&type=smp

    Browse Through More Reports Similar to the Global Lumbosacral Radicular Pain Management Market 2026, By The Business Research Company

    Pain Management Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Topical Pain Relief Market Report 2026

    https://www.thebusinessresearchcompany.com/report/topical-pain-relief-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • A Notable Trend in the Lumbosacral Radicular Pain Management Market Is the Development of Non-Opioid Therapies Targeting Nav1.8

    A Notable Trend in the Lumbosacral Radicular Pain Management Market Is the Development of Non-Opioid Therapies Targeting Nav1.8

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Forecasted Market Value Of The Lumbosacral Radicular Pain Management Market Across 2026–2030?

    The lumbosacral radicular pain management market size has seen robust growth in recent years. It is projected to expand from $0.9 billion in 2025 to $0.95 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. This growth witnessed in the past can be attributed to an increase in cases of spinal disc disorders, a reliance on pharmacological pain relief, the provision of hospital-based pain treatment, a rise in orthopedic consultations, and the development of physical therapy services.

    The lumbosacral radicular pain management market is projected to experience robust expansion over the coming years. This market is anticipated to reach $1.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. Key drivers for this growth during the projected period include the increasing aging population, a rising need for long-term pain management solutions, the uptake of non-invasive treatments, the expansion of home-based rehabilitation services, and innovations in pain diagnostics. Significant trends expected during this forecast span encompass a surging preference for multimodal pain management approaches, the greater embrace of non-opioid therapies, an increase in physical therapy-based interventions, the growing call for minimally invasive pain procedures, and the incorporation of personalized pain management strategies.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24592&type=smp

    What Major Growth Drivers Are Shaping The Outlook Of The Lumbosacral Radicular Pain Management Market?

    The increasing occurrence of back ailments is anticipated to fuel the expansion of the lumbosacral radicular pain management market moving ahead. These disorders encompass various conditions impacting the spine, its muscles, or nerves within the back, leading to unease or discomfort. The growing frequency of back pain issues stems from inactive lifestyles, which contribute to weakened back muscles, resulting in poor posture and ongoing pain. The goal of lumbosacral radicular pain management is to alleviate irritation of nerve roots in the lower back, thereby decreasing pain and inflammation. This management approach helps restore mobility and enhances the overall quality of life. As an illustration, in June 2024, data from the Australian Institute of Health and Welfare, a government agency located in Australia, indicated that in 2023, back issues constituted the third principal factor contributing to the disease burden in Australia, accounting for 4.3% of the country’s total disease burden. Consequently, the increasing incidence of back pain disorders is a key driver for the expansion of the lumbosacral radicular pain management market.

    What Segmentation Levels Are Considered In The Lumbosacral Radicular Pain Management Market?

    The lumbosacral radicular pain management market covered in this report is segmented –

    1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

    2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

    3) By Route Of Administration: Oral, Topical

    4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

    Subsegments:

    1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

    2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

    3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

    4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

    5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

    What Trends Are Projected To Affect The Lumbosacral Radicular Pain Management Market?

    Key companies operating in the lumbosacral radicular pain management market are prioritizing the development of advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to deliver a non-opioid alternative for enduring pain relief. An investigational oral NaV1.8 pain signal inhibitor is a medication in its trial stage that specifically targets the NaV1.8 sodium channel, recognized as a primary pathway for pain transmission through sensory nerves. For instance, in December 2024, Vertex Pharmaceuticals, a US-based biotech firm, released the outcomes from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study successfully achieved its primary endpoint, revealing a statistically significant and clinically meaningful reduction in pain from baseline in the suzetrigine group. Suzetrigine was generally well-tolerated, with no serious adverse events reported. Vertex intends to address the notable placebo response in subsequent Phase 3 trials to more accurately assess the drug’s efficacy.

    Which Leading Firms Are Contributing To The Growth Of The Lumbosacral Radicular Pain Management Market?

    Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

    Read the full lumbosacral radicular pain management market report here:

    https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report

    Which Regions Are Projected To Dominate The Lumbosacral Radicular Pain Management Market In The Coming Years?

    North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Lumbosacral Radicular Pain Management Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24592&type=smp

    Browse Through More Reports Similar to the Global Lumbosacral Radicular Pain Management Market 2026, By The Business Research Company

    Pain Management Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Topical Pain Relief Market Report 2026

    https://www.thebusinessresearchcompany.com/report/topical-pain-relief-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • A Notable Trend in the Lumbosacral Radicular Pain Management Market Is the Development of Non-Opioid Therapies Targeting Nav1.8

    A Notable Trend in the Lumbosacral Radicular Pain Management Market Is the Development of Non-Opioid Therapies Targeting Nav1.8

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Forecasted Market Value Of The Lumbosacral Radicular Pain Management Market Across 2026–2030?

    The lumbosacral radicular pain management market size has seen robust growth in recent years. It is projected to expand from $0.9 billion in 2025 to $0.95 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.7%. This growth witnessed in the past can be attributed to an increase in cases of spinal disc disorders, a reliance on pharmacological pain relief, the provision of hospital-based pain treatment, a rise in orthopedic consultations, and the development of physical therapy services.

    The lumbosacral radicular pain management market is projected to experience robust expansion over the coming years. This market is anticipated to reach $1.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. Key drivers for this growth during the projected period include the increasing aging population, a rising need for long-term pain management solutions, the uptake of non-invasive treatments, the expansion of home-based rehabilitation services, and innovations in pain diagnostics. Significant trends expected during this forecast span encompass a surging preference for multimodal pain management approaches, the greater embrace of non-opioid therapies, an increase in physical therapy-based interventions, the growing call for minimally invasive pain procedures, and the incorporation of personalized pain management strategies.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24592&type=smp

    What Major Growth Drivers Are Shaping The Outlook Of The Lumbosacral Radicular Pain Management Market?

    The increasing occurrence of back ailments is anticipated to fuel the expansion of the lumbosacral radicular pain management market moving ahead. These disorders encompass various conditions impacting the spine, its muscles, or nerves within the back, leading to unease or discomfort. The growing frequency of back pain issues stems from inactive lifestyles, which contribute to weakened back muscles, resulting in poor posture and ongoing pain. The goal of lumbosacral radicular pain management is to alleviate irritation of nerve roots in the lower back, thereby decreasing pain and inflammation. This management approach helps restore mobility and enhances the overall quality of life. As an illustration, in June 2024, data from the Australian Institute of Health and Welfare, a government agency located in Australia, indicated that in 2023, back issues constituted the third principal factor contributing to the disease burden in Australia, accounting for 4.3% of the country’s total disease burden. Consequently, the increasing incidence of back pain disorders is a key driver for the expansion of the lumbosacral radicular pain management market.

    What Segmentation Levels Are Considered In The Lumbosacral Radicular Pain Management Market?

    The lumbosacral radicular pain management market covered in this report is segmented –

    1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

    2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

    3) By Route Of Administration: Oral, Topical

    4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

    Subsegments:

    1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

    2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

    3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

    4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

    5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

    What Trends Are Projected To Affect The Lumbosacral Radicular Pain Management Market?

    Key companies operating in the lumbosacral radicular pain management market are prioritizing the development of advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to deliver a non-opioid alternative for enduring pain relief. An investigational oral NaV1.8 pain signal inhibitor is a medication in its trial stage that specifically targets the NaV1.8 sodium channel, recognized as a primary pathway for pain transmission through sensory nerves. For instance, in December 2024, Vertex Pharmaceuticals, a US-based biotech firm, released the outcomes from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study successfully achieved its primary endpoint, revealing a statistically significant and clinically meaningful reduction in pain from baseline in the suzetrigine group. Suzetrigine was generally well-tolerated, with no serious adverse events reported. Vertex intends to address the notable placebo response in subsequent Phase 3 trials to more accurately assess the drug’s efficacy.

    Which Leading Firms Are Contributing To The Growth Of The Lumbosacral Radicular Pain Management Market?

    Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

    Read the full lumbosacral radicular pain management market report here:

    https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report

    Which Regions Are Projected To Dominate The Lumbosacral Radicular Pain Management Market In The Coming Years?

    North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Lumbosacral Radicular Pain Management Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24592&type=smp

    Browse Through More Reports Similar to the Global Lumbosacral Radicular Pain Management Market 2026, By The Business Research Company

    Pain Management Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Topical Pain Relief Market Report 2026

    https://www.thebusinessresearchcompany.com/report/topical-pain-relief-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Facet-Joint Injection Market 2026 driven by pain management demand

    Facet-Joint Injection Market 2026 driven by pain management demand

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Market Size Of The Facet-Joint Injection Market In 2026 And What Value Is Projected For 2030?

    The facet-joint injection market has demonstrated robust growth in recent years. It is anticipated to expand from $2.97 billion in 2025 to $3.18 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.9%. This historical growth can be attributed to the rising prevalence of spinal degeneration, the incidence of arthritis, increasing awareness regarding pain management, the application of corticosteroids, and the growth in outpatient procedures.

    The facet-joint injection market size is projected to experience robust expansion over the coming years. It is anticipated to reach $4.1 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.6%. This expansion during the forecast period is primarily fueled by factors such as an aging population, a preference for minimally invasive treatments, the widespread occurrence of chronic pain, the growth of ambulatory care, and the increasing use of imaging-guided procedures. Key trends anticipated during this period encompass a surging demand for minimally invasive pain procedures, greater application in managing chronic back pain, the proliferation of outpatient pain clinics, the integration of image-guided injection methods, and the broadening of ambulatory surgical centers.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

    What Major Drivers Are Influencing Demand In The Facet-Joint Injection Market?

    The increasing incidence of spinal conditions and persistent back pain is anticipated to fuel the expansion of the facet-joint injection market. These long-term ailments, such as disc degeneration, arthritis, or nerve compression, affect the spine, leading to ongoing discomfort, restricted movement, and a diminished quality of life. The growing occurrence of spinal diseases and chronic back pain is largely attributed to inactive lifestyles and improper posture habits, prompting individuals to seek efficient and minimally disruptive treatments to alleviate persistent pain and regain functional mobility. Facet-joint injections provide assistance for spinal diseases and chronic back pain by mitigating spinal pain and inflammation, thereby offering relief to those suffering from these increasing problems. For instance, in May 2023, Spinal Cord Inc., a US-based non-profit resource center, reported approximately 18,000 new spinal cord injury (SCI) cases annually in the United States in 2023, with an estimated 302,000 individuals nationwide currently living with such injuries. Consequently, the rising prevalence of spinal diseases and chronic back pain is a significant factor driving the growth of the facet-joint injection market.

    What Are The Key Segments Of The Facet-Joint Injection Market?

    The facet-joint injection market covered in this report is segmented –

    1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

    2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

    3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

    2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

    3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

    4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

    What Key Trends Are Influencing The Development Of The Facet-Joint Injection Market?

    Major companies within the facet-joint injection market are concentrating on developing innovative products, such as facet fusion systems, to provide more lasting relief and enhance treatment results. Facet fusion systems are defined as medical devices engineered to stabilize and fuse the spine’s facet joints by stimulating bone growth between adjacent vertebrae. As an illustration, in March 2025, Aurora Spine Corporation, a US-based medical device enterprise, announced that the AEROTM Facet Fusion System, its latest product, obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system incorporates a titanium plasma spray coating to improve osseointegration and fusion potential. It accommodates multiple implant sizes to fit diverse patient anatomies and features radiolucent instrumentation to boost intraoperative visibility. These collective attributes aim to enhance procedural efficiency and achieve superior long-term outcomes in managing chronic back pain stemming from facet joint disorders.

    Who Are The Leading Companies Operating In The Facet-Joint Injection Market?

    Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

    Read the full facet-joint injection market report here:

    https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

    Which Region Shows The Strongest Potential For Future Growth In The Facet-Joint Injection Market?

    North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Facet-Joint Injection Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24531&type=smp

    Browse Through More Reports Similar to the Global Facet-Joint Injection Market 2026, By The Business Research Company

    Self Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/self-injections-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Facial Injectable Market Report 2026

    https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Facet-Joint Injection Market Performance Outlook 2026–2030: Revenue to Hit $4.1 Billion at 6.6% CAGR

    Facet-Joint Injection Market Performance Outlook 2026–2030: Revenue to Hit $4.1 Billion at 6.6% CAGR

    Uncover key drivers, emerging technologies, and competitive movements shaping the facet-joint injection market from 2026–2035 with trusted insights from The Business Research Company

    What market expansion outlook does the Facet-Joint Injection Market show for the 2026–2030 period?

    The facet-joint injection market has experienced significant expansion in recent years. This market is expected to increase from $2.97 billion in 2025 to $3.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.9%. The market’s past growth is attributable to factors such as the widespread occurrence of spinal degeneration, the incidence of arthritis, heightened awareness of pain management, the application of corticosteroids, and the rise in outpatient procedures.

    The facet-joint injection market size is projected to experience robust expansion over the coming years. It is anticipated to reach $4.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period can be attributed to factors such as an aging population, a preference for minimally invasive treatments, the widespread occurrence of chronic pain, the expansion of ambulatory care, and the increasing use of imaging-guided procedures. Furthermore, major trends expected in this timeframe include a surging demand for minimally invasive pain interventions, greater application in managing chronic back pain, the proliferation of outpatient pain clinics, the incorporation of image-guided injection methods, and the ongoing growth of ambulatory surgical centers.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

    What Drivers Are Shaping The Development Of The Facet-Joint Injection Market?

    The expansion of the facet-joint injection market is anticipated to be fueled by the increasing occurrence of spinal ailments and persistent back discomfort. These conditions are defined as enduring issues impacting the spine, such as disc degeneration, arthritis, or nerve compression, resulting in ongoing pain, restricted movement, and a diminished quality of life. The rise in these conditions is linked to inactive lifestyles and poor posture habits, prompting individuals to seek effective, minimally disruptive treatments for lasting relief and restored function. Facet-joint injections address spinal diseases and chronic back pain by alleviating pain and inflammation in the spine, offering succor to those afflicted by these growing health challenges. As an illustration, in May 2023, Spinal Cord Inc., a US-based non-profit resource center, reported approximately 18,000 new spinal cord injury (SCI) cases annually in the United States in 2023, with an estimated 302,000 individuals currently living with spinal cord injuries nationwide. Consequently, the increasing incidence of spinal diseases and chronic back pain is a significant driver for the growth of the facet-joint injection market. The increasing preference for minimally invasive medical interventions, driven by desires for quicker recovery and reduced post-operative discomfort, is anticipated to boost the growth of the facet-joint injection market. Minimally invasive procedures are medical treatments performed with small incisions or without significant surgical cutting. Their rise stems from patients seeking shorter healing times and less pain following operations. Facet-joint injections contribute to these minimally invasive approaches by delivering precise pain relief and accurate diagnosis without the need for extensive surgical intervention. For instance, in 2023, the American Society of Plastic Surgeons, a US-based specialty organization, reported that the total number of minimally invasive cosmetic procedures grew from 23.7 million in 2022 to 25.4 million in 2023. This growing demand for minimally invasive procedures is therefore a key factor driving the expansion of the facet-joint injection market.

    What Segment Types Are Examined In The Facet-Joint Injection Market?

    The facet-joint injection market covered in this report is segmented –

    1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

    2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

    3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

    2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

    3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

    4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

    Which Innovation Trends Are Advancing Developments Within The Facet-Joint Injection Market?

    Leading companies within the facet-joint injection market are focusing on developing innovative products, such as facet fusion systems, to offer longer-lasting relief and improve treatment outcomes. These systems are medical apparatuses engineered to stabilize and join spinal facet joints by fostering bone development between neighboring vertebrae. For instance, Aurora Spine Corporation, a US-based medical device firm, declared in March 2025 that its newest product, the AEROTM Facet Fusion System, obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system incorporates a titanium plasma spray coating to enhance bone integration and its capacity for fusion. It accommodates various implant sizes to suit diverse patient anatomies and includes radiolucent tools to improve visibility during surgery. Together, these attributes are designed to boost the efficiency of procedures and improve long-term results when addressing chronic back pain stemming from facet joint disorders.

    Who Are The Top-Performing Companies In The Facet-Joint Injection Market In Recent Years?

    Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

    Which Region Currently Holds The Largest Share Of The Facet-Joint Injection Market?

    North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Facet-Joint Injection Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24531&type=smp

    Browse Through More Reports Similar to the Global Facet-Joint Injection Market 2026, By The Business Research Company

    Self Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/self-injections-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Facial Injectable Market Report 2026

    https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Facet-Joint Injection Market Performance Outlook 2026–2030: Revenue to Hit $4.1 Billion at 6.6% CAGR

    Uncover key drivers, emerging technologies, and competitive movements shaping the facet-joint injection market from 2026–2035 with trusted insights from The Business Research Company

    What market expansion outlook does the Facet-Joint Injection Market show for the 2026–2030 period?

    The facet-joint injection market has experienced significant expansion in recent years. This market is expected to increase from $2.97 billion in 2025 to $3.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.9%. The market’s past growth is attributable to factors such as the widespread occurrence of spinal degeneration, the incidence of arthritis, heightened awareness of pain management, the application of corticosteroids, and the rise in outpatient procedures.

    The facet-joint injection market size is projected to experience robust expansion over the coming years. It is anticipated to reach $4.1 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This growth during the forecast period can be attributed to factors such as an aging population, a preference for minimally invasive treatments, the widespread occurrence of chronic pain, the expansion of ambulatory care, and the increasing use of imaging-guided procedures. Furthermore, major trends expected in this timeframe include a surging demand for minimally invasive pain interventions, greater application in managing chronic back pain, the proliferation of outpatient pain clinics, the incorporation of image-guided injection methods, and the ongoing growth of ambulatory surgical centers.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

    What Drivers Are Shaping The Development Of The Facet-Joint Injection Market?

    The expansion of the facet-joint injection market is anticipated to be fueled by the increasing occurrence of spinal ailments and persistent back discomfort. These conditions are defined as enduring issues impacting the spine, such as disc degeneration, arthritis, or nerve compression, resulting in ongoing pain, restricted movement, and a diminished quality of life. The rise in these conditions is linked to inactive lifestyles and poor posture habits, prompting individuals to seek effective, minimally disruptive treatments for lasting relief and restored function. Facet-joint injections address spinal diseases and chronic back pain by alleviating pain and inflammation in the spine, offering succor to those afflicted by these growing health challenges. As an illustration, in May 2023, Spinal Cord Inc., a US-based non-profit resource center, reported approximately 18,000 new spinal cord injury (SCI) cases annually in the United States in 2023, with an estimated 302,000 individuals currently living with spinal cord injuries nationwide. Consequently, the increasing incidence of spinal diseases and chronic back pain is a significant driver for the growth of the facet-joint injection market. The increasing preference for minimally invasive medical interventions, driven by desires for quicker recovery and reduced post-operative discomfort, is anticipated to boost the growth of the facet-joint injection market. Minimally invasive procedures are medical treatments performed with small incisions or without significant surgical cutting. Their rise stems from patients seeking shorter healing times and less pain following operations. Facet-joint injections contribute to these minimally invasive approaches by delivering precise pain relief and accurate diagnosis without the need for extensive surgical intervention. For instance, in 2023, the American Society of Plastic Surgeons, a US-based specialty organization, reported that the total number of minimally invasive cosmetic procedures grew from 23.7 million in 2022 to 25.4 million in 2023. This growing demand for minimally invasive procedures is therefore a key factor driving the expansion of the facet-joint injection market.

    What Segment Types Are Examined In The Facet-Joint Injection Market?

    The facet-joint injection market covered in this report is segmented –

    1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

    2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints

    3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone

    2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine

    3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

    4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations

    Which Innovation Trends Are Advancing Developments Within The Facet-Joint Injection Market?

    Leading companies within the facet-joint injection market are focusing on developing innovative products, such as facet fusion systems, to offer longer-lasting relief and improve treatment outcomes. These systems are medical apparatuses engineered to stabilize and join spinal facet joints by fostering bone development between neighboring vertebrae. For instance, Aurora Spine Corporation, a US-based medical device firm, declared in March 2025 that its newest product, the AEROTM Facet Fusion System, obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system incorporates a titanium plasma spray coating to enhance bone integration and its capacity for fusion. It accommodates various implant sizes to suit diverse patient anatomies and includes radiolucent tools to improve visibility during surgery. Together, these attributes are designed to boost the efficiency of procedures and improve long-term results when addressing chronic back pain stemming from facet joint disorders.

    Who Are The Top-Performing Companies In The Facet-Joint Injection Market In Recent Years?

    Major companies operating in the facet-joint injection market are Abbott Laboratories, B. Braun Melsungen AG, BD (Becton Dickinson and Company), Cook Medical, Teleflex Incorporated, Merit Medical Systems Inc., Halyard Health, ICU Medical Inc., Pajunk GmbH Medizintechnologie, Avanos Medical Inc., Vygon SA, Cardinal Health Inc., Terumo Corporation, Nipro Corporation, Septodont Holding, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Piramal Pharma Limited, Intas Pharmaceuticals Ltd., Gland Pharma Limited, Amphastar Pharmaceuticals Inc., Fresenius Medical Care, Baxter International Inc., McKesson Corporation

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

    Which Region Currently Holds The Largest Share Of The Facet-Joint Injection Market?

    North America was the largest region in the facet-joint injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Facet-Joint Injection Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24531&type=smp

    Browse Through More Reports Similar to the Global Facet-Joint Injection Market 2026, By The Business Research Company

    Self Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/self-injections-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Facial Injectable Market Report 2026

    https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Lumbosacral Radicular Pain Management Market Report 2026: Strategic Insights and Revenue Outlook

    Lumbosacral Radicular Pain Management Market Report 2026: Strategic Insights and Revenue Outlook

    Uncover key drivers, emerging technologies, and competitive movements shaping the lumbosacral radicular pain management market from 2026–2035 with trusted insights from The Business Research Company

    How much larger will the Lumbosacral Radicular Pain Management Market be in 2030 compared with 2026?

    The lumbosacral radicular pain management market has demonstrated robust expansion in recent years. This market is anticipated to expand from $0.9 billion in 2025 to $0.95 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.7%. The historical growth of this market can be attributed to an increase in spinal disc disorders, a widespread dependence on pharmacological pain relief, the availability of hospital-based pain treatment, a rise in orthopedic consultations, and the development of physical therapy services.

    The lumbosacral radicular pain management market size is projected to experience robust growth in the coming years, expanding to $1.17 billion by 2030, with a compound annual growth rate (CAGR) of 5.4%. This anticipated expansion during the forecast period is driven by factors such as the increasing aging population, a growing need for long-term pain management solutions, the uptake of non-invasive therapies, the growth of home-based rehabilitation, and innovations in pain diagnostics. Prominent trends expected in this period include an increasing preference for multimodal pain management, a greater adoption of non-opioid treatments, the broadening of physical therapy-based interventions, a rising demand for minimally invasive pain treatments, and the incorporation of personalized pain management plans.

    Access Your Free Sample Report for In-Depth Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24592&type=smp

    What Drivers Are Guiding Growth Patterns In The Lumbosacral Radicular Pain Management Market?

    The increasing occurrence of back pain conditions is anticipated to fuel the expansion of the lumbosacral radicular pain management market in the future. These disorders encompass various ailments impacting the spine, its muscles, or nerves in the back, leading to discomfort or soreness. The growing incidence of back pain issues stems from inactive lifestyles, which tend to weaken spinal muscles, resulting in poor posture and chronic discomfort. The goal of lumbosacral radicular pain management is to alleviate irritation of nerve roots in the lower back, thereby decreasing pain and inflammation. This approach helps restore movement and enhance life quality. For example, data from June 2024, provided by the Australian Institute of Health and Welfare, a government body in Australia, indicated that in 2023, back issues ranked as the third primary factor contributing to the disease burden in Australia, accounting for 4.3% of the nation’s overall disease burden. Consequently, the increased occurrence of back pain disorders is a key impetus for the expansion of the lumbosacral radicular pain management market.

    How Is The Lumbosacral Radicular Pain Management Market Divided Into Segments?

    The lumbosacral radicular pain management market covered in this report is segmented –

    1) By Medication: Non-Steroidal Anti-Inflammatory Drugs, Opioids, Antidepressants, Anticonvulsants, Steroids

    2) By Physical Therapy: Manual Therapy, Exercise Therapy, Electrotherapy, Thermal Therapy, Hydrotherapy

    3) By Route Of Administration: Oral, Topical

    4) By End-User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

    Subsegments:

    1) By Non-Steroidal Anti-Inflammatory Drugs: Ibuprofen, Naproxen, Diclofenac, Celecoxib, Etoricoxib

    2) By Opioids: Tramadol, Oxycodone, Morphine, Hydrocodone, Fentanyl

    3) By Antidepressants: Amitriptyline, Nortriptyline, Duloxetine, Desvenlafaxine, Venlafaxine

    4) By Anticonvulsants: Gabapentin, Pregabalin, Carbamazepine, Lamotrigine, Topiramate

    5) By Steroids: Dexamethasone, Methylprednisolone, Prednisone, Triamcinolone, Hydrocortison

    Which Innovation Trends Are Advancing Developments Within The Lumbosacral Radicular Pain Management Market?

    Leading companies active in the lumbosacral radicular pain management market are prioritizing the development of advanced treatments, such as investigational oral NaV1.8 pain signal inhibitors, to provide a non-opioid alternative for enduring pain relief. An investigational oral NaV1.8 pain signal inhibitor is a medication in its trial phase designed to target the NaV1.8 sodium channel, which serves as a crucial pathway for pain transmission through sensory nerves. As an illustration, in December 2024, Vertex Pharmaceuticals, a US-based biotech company, announced the findings from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR). The study fulfilled its primary endpoint, revealing a statistically significant and clinically impactful reduction in pain from the outset in the suzetrigine group. Suzetrigine was generally tolerated without issue, with no serious adverse events reported. Vertex aims to address the substantial placebo response in subsequent Phase 3 trials to better ascertain the drug’s efficacy.

    Which Key Players Are Driving Competition In The Lumbosacral Radicular Pain Management Market?

    Major companies operating in the lumbosacral radicular pain management market are Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, GSK plc, Medtronic plc, Eli Lilly and Company, Amgen Inc, Koninklijke Philips NV, Stryker Corporation, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Dr Reddy’s Laboratories Ltd, NuVasive Inc., Nobel Biocare Holdings AG, Ultradent Products Inc., Nevro Corp., Zynex Inc., Eliem Therapeutics, Vertebral Technologies Inc., Semnur Pharmaceuticals Inc.

    Access The Complete Report For Deeper Market Insights:

    https://www.thebusinessresearchcompany.com/report/lumbosacral-radicular-pain-management-global-market-report

    Which Region Is Projected To Lead The Lumbosacral Radicular Pain Management Market During The Forecast Period?

    North America was the largest region in the lumbosacral radicular pain management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lumbosacral radicular pain management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request Your Customized Lumbosacral Radicular Pain Management Market Research Report for Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=24592&type=smp

    Browse Through More Reports Similar to the Global Lumbosacral Radicular Pain Management Market 2026, By The Business Research Company

    Pain Management Drugs Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pain-management-drugs-global-market-report

    Joint Pain Injections Market Report 2026

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Topical Pain Relief Market Report 2026

    https://www.thebusinessresearchcompany.com/report/topical-pain-relief-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Facet-Joint Injection Market Growth Opportunities: Insights from 2025–2029

    Facet-Joint Injection Market Growth Opportunities: Insights from 2025–2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    What Is The Anticipated Size Of The Facet-Joint Injection Market Over The Five-Year Period 2025–2029?

    The facet-joint injection market has experienced significant growth in recent years. It is anticipated to expand from $2.78 billion in 2024 to $2.97 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.0%. This historical expansion can be attributed to a rise in chronic back and neck pain incidents, the increasing adoption of minimally invasive pain management therapies, an expanding aging demographic with spinal degeneration, greater access to image-guided injection methods, and heightened awareness of non-surgical options for pain relief.

    The facet-joint injection market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $3.85 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.7%. This projected growth during the forecast period stems from factors such as an escalating need for non-opioid approaches to pain management, the wider uptake of image-guided injection techniques, an increased emphasis on outpatient and day-care interventions, the broader application of regenerative injection therapies, and a rise in healthcare spending directed towards spinal disorder treatments. Key trends anticipated during this period encompass progress in ultrasound and fluoroscopy-guided injections, enhanced drug formulations designed for prolonged pain relief, the emergence of combination therapies for joint discomfort, breakthroughs in regenerative treatments like platelet-rich plasma and stem cells, and developments in wearable technology for monitoring after injections.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24531&type=smp

    Which Industry Drivers Are Expected To Accelerate The Facet-Joint Injection Market From 2025 To 2029?

    The increasing incidence of spinal conditions and persistent back discomfort is projected to fuel the expansion of the facet-joint injection market in the coming years. These long-term ailments, such as disc degeneration, arthritis, or nerve compression, lead to ongoing pain, restricted movement, and a diminished quality of life. The escalating occurrence of spinal diseases and chronic back pain stems from inactive lifestyles and inadequate posture, prompting individuals to seek effective yet minimally disruptive treatments to alleviate discomfort and restore functional capacity. Facet-joint injections provide relief for these conditions by mitigating spinal pain and inflammation. For instance, in May 2023, Spinal Cord Inc., a US-based non-profit resource center, indicated that approximately 18,000 new spinal cord injury (SCI) cases are reported each year in the United States in 2023, with an estimated 302,000 people currently living with such injuries nationwide. Consequently, the growing prevalence of spinal diseases and chronic back pain is a significant driver for the facet-joint injection market’s growth.

    What Are The Segment Types Shaping The Facet-Joint Injection Market?

    The facet-joint injection market covered in this report is segmented –

    1) By Product Type: Corticosteroids, Local Anesthetics, Hyaluronic Acid, Other Product Types

    2) By Application: Cervical Facet Joints, Thoracic Facet Joints, Lumbar Facet Joints, Facet Joint Injections

    3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

    Subsegments:

    1) By Corticosteroids: Triamcinolone Acetonide, Methylprednisolone Acetate, Dexamethasone Sodium Phosphate, Betamethasone, Other Corticosteroids

    2) By Local Anesthetics: Lidocaine, Bupivacaine, Ropivacaine, Prilocaine, Other Local Anesthetics

    3) By Hyaluronic Acid: High Molecular Weight Hyaluronic Acid, Low Molecular Weight Hyaluronic Acid, Cross-Linked Hyaluronic Acid, Non-Cross-Linked Hyaluronic Acid

    4) By Other Product Types: Platelet-Rich Plasma, Biological Agents, Combination Formulations, Other Injectables

    What Are The Latest Industry Trends Transforming The Facet-Joint Injection Market?

    Leading companies in the facet-joint injection market are concentrating on developing innovative products, such as facet fusion systems, to provide more enduring relief and enhance treatment outcomes. Facet fusion systems are medical devices specifically designed to stabilize and fuse the facet joints of the spine by promoting bone growth between adjacent vertebrae. For instance, in March 2025, Aurora Spine Corporation, a US-based medical device company, announced that the AEROTM Facet Fusion System, its newest product, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The system integrates titanium plasma spray coating to improve osseointegration and its fusion potential. It also supports multiple implant sizes to accommodate varied patient anatomies and offers radiolucent instrumentation to enhance intraoperative visibility. Collectively, these features aim to improve procedural efficiency and long-term outcomes in treating chronic back pain caused by facet joint disorders.

    Which Industry Leaders Are Driving Innovation Across The Facet-Joint Injection Market?

    Major companies operating in the facet-joint injection market are Pfizer Inc., Merck & Co. Inc, AbbVie Inc., Sanofi S.A., Medtronic plc, Stryker Corporation, Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Henry Schein Inc., Bausch Health Companies Inc., Zimmer Biomet Holdings Inc., Smith & Nephew plc, Dr. Reddy’s Laboratories Ltd., Arthrex Inc., Aspen Pharmacare Holdings Limited, Pacira BioSciences Inc., Bioventus Inc., Ferring Pharmaceuticals, Anika Therapeutics Inc., Symbiotec Pharmalab Pvt. Ltd.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/facet-joint-injection-global-market-report

    Which Region Currently Holds The Largest Share Of The Facet-Joint Injection Market?

    North America was the largest region in the facet-joint injection market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the facet-joint injection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Facet-Joint Injection Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=24531&type=smp

    Browse Through More Reports Similar to the Global Facet-Joint Injection Market 2025, By The Business Research Company

    Self Injections Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/self-injections-global-market-report

    Joint Pain Injections Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/joint-pain-injections-global-market-report

    Facial Injectable Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/facial-injectable-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model